Stocktoria
MetaVia Inc. MTVA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-08-05
MetaVia Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $6.8M | $21.6M | — | — | — |
| Operating income | -$13.7M | -$28.8M | -$15.9M | -$19.6M | -$15.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$13.0M | -$27.6M | -$12.5M | -$14.0M | -$15.3M |
| EPS (diluted) | $-7.35 | $-39.13 | $-2.46 | $-43.42 | $-19.81 |
| Operating cash flow | -$15.7M | -$24.7M | -$10.8M | -$11.7M | -$15.1M |
| Free cash flow | -$15.7M | -$24.7M | -$10.8M | — | -$15.1M |
| Cash & equivalents | $10.3M | $16.0M | $22.4M | $33.4M | $16.4M |
| Total assets | $11.1M | $16.3M | $22.8M | $33.5M | $16.8M |
| Total liabilities | $5.8M | $8.3M | $6.1M | $11.8M | $2.2M |
| Shareholders' equity | $5.3M | $7.9M | $16.7M | $21.8M | $14.6M |
Source: SEC EDGAR filings · CIK 0001638287 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.